Related Experiment Videos
Follicular lymphoma: time for a re-think?
Maher K Gandhi1, Robert E Marcus
1Department of Haematology, Princess Alexandra Hospital, Brisbane, 4006 QLD, Australia. maherG@qimr.edu.au
Blood Reviews
|March 8, 2005
Summary
New follicular lymphoma (FL) treatments, including rituximab, show promise for this indolent Non-Hodgkin
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Follicular lymphoma (FL) is the most common indolent Non-Hodgkin's lymphoma.
- FL is generally incurable, characterized by a relapsing-remitting course.
- Localized disease represents a subset with potential for cure.
Purpose of the Study:
- To review novel therapeutic approaches for follicular lymphoma.
- To evaluate the efficacy and integration of new treatments into standard care.
- To discuss the potential impact of emerging therapies on FL management.
Main Methods:
- Review of recent clinical data and therapeutic strategies.
- Analysis of novel agents including anti-CD20 antibodies, BCL-2 inhibitors, and radioimmunotherapy.
- Assessment of anti-idiotype vaccination and new chemotherapeutic agents.
Main Results:
- Rituximab (anti-CD20 antibody) demonstrates excellent efficacy and a favorable toxicity profile.
- Emerging therapies offer guarded optimism for managing FL.
- Long-term survival data for rituximab is pending.
Conclusions:
- Novel treatments are transforming follicular lymphoma care.
- Integration of rituximab and other agents into standard protocols is crucial.
- Further research is needed to establish long-term benefits and optimal treatment sequencing.